top of page
NEWSROOM
Subscribe for News and Insights
Thanks for submitting!
Subscribe
CLIENT & PORTFOLIO NEWS
SETH YAKATAN NEWS & MEDIA
ARCHIVE
Search
Biogen's aducanumab crosses FDA finish line just in time to save its business
The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. The FDA’s approval on Monday is set to...
bottom of page
